Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals — Investor Presentation (January 2019)

39 slides from Constellation Pharmaceuticals's investor presentation, Jan 7, 2019

  1. Slide 1: Developing Next-Generation Epigenetic Treatments for Cancer Patients

    Developing Next-Generation Epigenetic Treatments for Cancer Patients Corporate Overview January 2019 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Company’s product candidates, the anticipated benefits of

  3. Slide 3: Epigenetics: Instructions for Genetic Code

    Epigenetics: Instructions for Genetic Code Tumor Cells MDSC NK Cell T Cell Focused on Three Distinct Classes That Chemically Modify Chromatin Tumor Microenvironment Target Transcriptional Networks That Result in Cell Death Re-program Immune Cells to Overcome Resistance to Cancer Immunotherapies Tran

  4. Slide 4: Constellation Highlights

    Two wholly owned clinical programs: CPI-0610 (BET) and CPI-1205 (EZH2) Constellation Highlights CPI-0610 has possible disease-modifying effects in myelofibrosis CPI-1205 has been well tolerated and active in clinical studies in combination with ARS inhibitors in prostate cancer Data updates in Q2 20

  5. Slide 5: Multiple Near-Term Opportunities for Success

    * Metastatic castration-resistant prostate cancer Multiple Near-Term Opportunities for Success Product Candidates Indications Preclinical Phase 1 Phase 2 Phase 3 Milestones BET Inhibitor CPI-0610 2L Myelofibrosis 1L Myelofibrosis 18 patients enrolled (Dec 2018) Interim data update in Q2 2019 EZH2 Fr

  6. Slide 6: Vision for 2019: A Year of Data

    Vision for 2019: A Year of Data 2019 Transition into a Late-Stage Oncology Development Company with an Exciting Pipeline of Development and Discovery Programs Generate positive POC and begin planning for pivotal registration studies with CPI-0610 and CPI-1205 Expand our EZH2 franchise by advancing C

  7. Slide 7: CPI-0610 BET Inhibitor

    CPI-0610 BET Inhibitor

  8. Slide 8: Control of Key Immune, Fibrotic, and Oncogenic Pathways in Myelofibrosis

    Control of Key Immune, Fibrotic, and Oncogenic Pathways Leads to Opportunity in Myelofibrosis (MF) BET Family of Proteins … Enhancer TSS BRD4 Transcription Factor … Fibrosis TGF-β target genes Immune Signaling NF-κB target genes Cancer Genetics MYC, BCL2

  9. Slide 9: Mechanism for Potential Disease Modification

    Suppress Bone Marrow Cells (Megakaryocytes) Driving MF and Reduce Inflammation Mechanism for Potential Disease Modification BET Signaling Differentiation of Myeloid Cells into Megakaryocytes Pro-Inflammatory Cytokines (e.g., IL-8) JAK/STAT Signaling STAT STAT Cytoplasm Nucleus NF-kB Target Genes BET

  10. Slide 10: In Vivo Support for BET Inhibition Enhancing JAK Inhibition in MF

    Kleppe et al., 2018 Cancer Cell In Vivo Support for BET Inhibition Enhancing JAK Inhibition in MF BET Inhibitor + Ruxolitinib Led to Synergistic Reduction in Spleen Improved Bone Marrow Fibrosis Score Vehicle 1–2+ JQ1 (BETi) 1+ Ruxolitinib 1+ Combo 0 * * *

  11. Slide 11: Myelofibrosis Background and Significant Unmet Need

    * Constellation Pharmaceuticals estimates; Europe 5 = UK, France, Germany, Italy, Spain ** Registered trademark of Incyte Corporation Myeloproliferative Neoplasm Leading to Bone Marrow Fibrosis and Impaired Hematopoiesis Myelofibrosis (MF) Background Ruxolitinib (Jakafi®**) Only Approved Therapy Rux

  12. Slide 12: Need for New Disease-Modifying Treatments in MF

    * Source: Mesa, R., et al. J Clin Oncol 2017: 35(34):3844-3850 ** Nicolosi et al. Leukemia 2018 32:1254–1258 Need for New Disease-Modifying Treatments in MF Spleen Response – SIMPLIFY-1* Transfusion Dependence – SIMPLIFY-1* JAK inhibitors exacerbate transfusion dependence 26.5% Spleen Response 29% S

  13. Slide 13: Potential for Disease Modification with CPI-0610 Treatment

    Spleen Volume Systemic Symptoms Anemia & Transfusion Dependence Bone Marrow Fibrosis Potential for Disease Modification with CPI-0610 Treatment Preliminary Data Suggest Potential Improvements with CPI-0610 Treatment

  14. Slide 14: CPI-0610 Overview

    Treated 138 patients in Phase 1 trials of various hematologic malignancies Preliminary clinical activity observed in: Myelofibrosis (Phase 2) Lymphoma – e.g., ABC-DLBCL (Phase 1) Signals of potential differentiated safety profile Phase 1 data suggest that thrombocytopenia (DLT) may be reversible and

  15. Slide 15: Development Plan to Expand the CPI-0610 Opportunity

    * Cohort 3 will enroll anemic patients, pivotal trial plans would include all comers Robust Development Plan to Expand the CPI-0610 Opportunity MANIFEST: Expanded Phase 2 Trial in MF Cohort 1A: 2L Transfusion Dependent (TD) n = up to 16 Cohort 1B: 2L Non-TD n = up to 25 Cohort 2A: 2L Transfusion Dep

  16. Slide 16: MANIFEST: Data Update on First Four 2L MF Patients

    Data cutoff December 10, 2018 MANIFEST: Data Update on First Four 2L MF Patients Treated Spleen Size Reduced in All Patients as Measured by MRI Best Spleen Response Reduced spleen size Symptom improvement One patient with thrombocytosis and one patient transfusion-dependent at baseline – both resolv

  17. Slide 17: Transfusion Independence and Improved Anemia and Platelet Count

    Data cutoff December 10, 2018 Transfusion Independence and Improved Anemia and Platelet Count in Rux-Resistant Patient Potential Improvement in Hematopoiesis After CPI-0610 Treatment Patient treated with CPI-0610 + ruxolitinib combination therapy No Transfusions for ≥ 52 Weeks Transfusions 4 wks 4 w

  18. Slide 18: Increasing Trends in Hemoglobin Levels in First Four Patients

    Data cutoff December 10, 2018 Increasing Trends in Hemoglobin Levels in First Four Patients Treated Potential for Improved Hematopoietic Function

  19. Slide 19: CPI-0610 Monotherapy Correlates with Improved Bone Marrow Fibrosis

    Baseline Baseline Cycle 17 Cycle 17 CPI-0610 as a Monotherapy Correlates with Improved Bone Marrow Fibrosis* *Reticulin stain; Not yet confirmed by central review MF Grade 3 MF Grade 2 MF Grade 2 MF Grade 1 Patient #3 Heavily Pre-treated ASXL1 and CALR Mutation Patient #4 Heavily Pre-Treated ASXL1 a

  20. Slide 20: Significant Expansion of Clinical Trial Operations

    # of Countries # of Clinical Sites # of Patients Enrolled Significant Expansion of Clinical Trial Operations Since Last Data Cutoff in May 2018 Most patients enrolled in study have poor prognosis Greater than 70% of patients have ASXL1 mutations Greater than 60% of patients ³ 3 different MF mutation

  21. Slide 21: MF as Rapid Path to First Approval for CPI-0610

    Deliver a therapy that can achieve disease modification as a monotherapy or in combination with JAK inhibitors Conversion of TD to TI Spleen volume reduction Symptom improvement Additional support: Reduced anemia Improvement in fibrosis grade Biomarkers: cytokine levels and allelic burden MF as Rapi

  22. Slide 22: CPI-1205 and CPI-0209 EZH2 Franchise

    CPI-1205 and CPI-0209 EZH2 Franchise

  23. Slide 23: EZH2 Inhibition Offers Broad Therapeutic Potential

    EZH2 “Writer” Activity Suppresses Gene Transcription EZH2 Inhibition Offers Broad Therapeutic Potential Polycomb Repressive Complex 2 (PRC2)… … Methylates Histone H3 at Lysine 27 (K27) EZH2 SUPPRESSED TRANSCRIPTION Acquired Drug Resistance: EZH2 mediates gene silencing that diminishes response to ex

  24. Slide 24: Model for EZH2 Role in Prostate Cancer

    Yu et al., Cancer Research 2007 *Signature of H3K27me3-occupied EZH2 target genes repressed in metastatic relative to clinically localized prostate cancer and benign prostate tissue Model for EZH2 Role in Prostate Cancer EZH2 Gene Signature* Predicts Outcomes in Prostate Cancer 0 2 4 6 8 10 1.0 0.9

  25. Slide 25: EZH2 Synergy with Androgen Receptor Signaling

    *Bradley, WD, et al., ”EZH2 Inhibition as an Effective Treatment for Metastatic Castration-Resistant Prostate Cancer,” presentation at 2018 EORTC/NCI/AACR meeting EZH2 Synergy with Androgen Receptor Signaling (ARS) CPI-1205 Intensifies Gene Expression Effects of Enzalutamide in Prostate Cancer Cells

  26. Slide 26: Current Treatment Paradigm in mCRPC

    Current Treatment Paradigm in mCRPC mCRPC 1st Line Abiraterone or Enzalutamide 2nd Line Enzalutamide or Abiraterone (Poor Activity) 3rd Line Chemotherapy or Palliative Care EZH2 inhibition may enhance the activity of ARS inhibitors and reduce need for chemotherapy Pre-Metastatic Prostate Cancer May

  27. Slide 27: 2L mCRPC Patients Suffer Poor Response Rate and Short Time to Progression

    *ASCO 2018 Poster Khalaf, et al. (Kim Chi lab) 2L mCRPC Patients Treated with Abiraterone or Enzalutamide Suffer Poor Response Rate and Short Time to Progression* GOAL Treat with CPI-1205 combination therapy to achieve deeper and more durable responses > PSA30 = 6% > PSA50 = 4% > PSA80 = 0% TTP = 1.

  28. Slide 28: Phase 2 Expanded to Include Enzalutamide and Abiraterone

    Note: In ProSTAR, abiraterone is dosed in combination with prednisone Phase 2 Expanded to Include Enzalutamide and Abiraterone ProSTAR Trial Design Testing Biomarkers for Patient Enrichment Enzalutamide + CPI-1205 (Progressed on Abiraterone) n = ~ 35 Enzalutamide Alone (Progressed on Abiraterone) n

  29. Slide 29: ProSTAR Update

    *Expansion cohort in advanced prostate cancer initiated to evaluate potential anti-tumor activity ProSTAR Update May 25, 2018 Data Recap 2 of 6 evaluable patients achieved PSA reduction of >80% 2 of 4 evaluable patients with CTCs achieved CTC reduction of >30% 2 of 2 evaluable patients had metastati

  30. Slide 30: Resolution of Bone Metastases: Example Patient 1

    *Continued on CPI-1205 monotherapy after cycle 1 Resolution of Bone Metastases Baseline Cycle 4 Day 1 CPI-1205 + Enzalutamide* Example Patient 1

  31. Slide 31: Objective Response by CT Scan: Example Patient 2

    Objective Response by CT Scan February 2018 Baseline: December 2017 CPI-1205 + Enzalutamide Example Patient 2

  32. Slide 32: Significant PSA Reduction in Heavily Pre-Treated Patient

    Significant PSA Reduction in Heavily Pre-Treated and Refractory Patient Experience with a Compassionate-Use Patient 3,000 2,500 2,000 1,500 1,000 500 12 agents prior to CPI-1205, including second-generation androgen inhibitors, chemotherapy, PARP inhibitors, tyrosine kinase inhibitors, checkpoint in

  33. Slide 33: CPI-1205 EZH2 Franchise Summary

    CPI-1205 EZH2 Franchise Summary Preclinical synergy with androgen receptor signaling (ARS) inhibitors ProSTAR Phase 1b demonstrates well-tolerated combinations and evidence of activity with either enzalutamide or abiraterone ProSTAR Phase 2 started Best-in-class potential with more comprehensive cov

  34. Slide 34: CPI-0209: Second-Generation EZH2 Inhibitor

    Lymphoma Xenograft – Mutated EZH2 Model Once-Daily Treatment Resulted in Rapid and Durable Tumor Regression CPI-0209: Second-Generation EZH2 Inhibitor CPI-0209 May Provide More Comprehensive EZH2 Coverage, Expanding Addressable Populations Cessation of treatment Prostate Cancer Xenograft – ARV7+ Mod

  35. Slide 35: Discovery Platform Fueling the Pipeline

    Discovery Platform Fueling the Pipeline Innate Adaptive Alter aberrant gene expression within cancer cells Increase tumor immunogenicity Re-program immune cells to overcome resistance to cancer immunotherapies Tumor Cells Immune Cells Discovery Programs Targeting Epigenetic Regulators on the Tumor a

  36. Slide 36: Financial/Operational Strength

    Financial/Operational Strength

  37. Slide 37: Strong Cash Position

    Post-IPO cash expected to fund operations into Q2 2020, including: Ongoing clinical trials to determine proof of concept for CPI-1205 and CPI-0610 Continued advancement of CPI-0209 Ongoing support for robust discovery/preclinical pipeline Oversubscribed crossover financing round in April raised $100

  38. Slide 38: Management Team

    Management Team Jigar Raythatha President and CEO Emma Reeve Chief Financial Officer Adrian Senderowicz, M.D. Chief Medical Officer Brad Prosek SVP, Corporate Development Robert Sims, PhD SVP, Research Patrick Trojer, PhD Chief Scientific Officer Karen Valentine Chief Legal Officer, General Counsel

  39. Slide 39: Potential Value Creation Catalysts

    Potential Value Creation Catalysts 2019 –Year of Data 2018 –Year of Execution 1H 2018 Complete crossover financing Expand enrollment in ProSTAR Initiate ORIOn-E Select 2nd generation EZH2 inhibitor candidate (CPI-0209) 2H 2018 Complete IPO Additional active sites in US, Canada / EU for CPI-0610 in m

Constellation Pharmaceuticals — Investor Presentation (January 2019) on 6ix